Table 2. Correlation between SII and clinicopathological features in patients with pancreatic cancer.
| Factors | Studies (n) | Patients (n) | OR (95%CI) | p | Effects model |
Heterogeneity
I2(%) Ph |
|
| Sex (male vs female) | 6 | 1,392 | 1.09(0.87-1.36) | 0.469 | FEM | 0 | 0.874 |
| Tumor location (Head vs body/tail) | 4 | 878 | 1.33(0.97-1.81) | 0.074 | FEM | 15.6 | 0.314 |
| Lymph node metastasis (Yes vs no) | 4 | 973 | 1.27(0.96-1.69) | 0.093 | FEM | 45.6 | 0.138 |
| TNM stage (III-IV vs I-III) | 4 | 973 | 1.02(0.63-1.66) | 0.798 | REM | 56.0 | 0.103 |
| Grade (3-4 vs 1-2) | 3 | 878 | 1.07(0.77-1.50) | 0.671 | FEM | 0 | 0.394 |
| Vascular invasion (Yes vs no) | 2 | 514 | 1.33(0.89-1.97) | 0.160 | FEM | 0 | 0.610 |
OR, odds ratio; CI, confidence interval; TNM, Tumor- Node- Metastasis; REM, random-effects model; FEM, fixed-effects model.